MedTrace Logo

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

NCT00002819 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-04-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. It is not yet known whether chemotherapy alone is more effective than chemotherapy plus peripheral stem cell transplantation for ovarian epithelial cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel and carboplatin with that of carboplatin, mitoxantrone, and cyclophosphamide followed by peripheral stem cell transplantation in treating patients who have persistent stage III or stage IV ovarian epithelial cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

mitoxantrone hydrochloride

DRUG

paclitaxel

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • SWOG Cancer Research Network

    collaborator NETWORK

  • Cancer and Leukemia Group B

    collaborator NETWORK

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • William P. McGuire, MD · Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center

  • Kenneth B. Miller, MD · Tufts Medical Center Cancer Center

  • Patrick J. Stiff, MD · Loyola University

  • Stephen L. Graziano, MD · State University of New York - Upstate Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30
Primary Completion
2000-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002819 on ClinicalTrials.gov